Photo credit: Getty Images
Topcon Healthcare & RetInSight join forces
May 7, 2025
Topcon Healthcare, Inc., a provider of medical devices and digital healthcare solutions, announced the acquisition of RetInSight GmbH, a privately held company based in Vienna, Austria, known for its retinal imaging AI solutions.
Topcon Healthcare says the acquisition advances Topcon Healthcare’s vision of “Healthcare from the Eye, enhancing access to intelligent diagnostics that increase access to high-quality eye care, reduce healthcare costs and improve clinical outcomes.”
Detecting & Monitoring Major Retinal Diseases
RetInSight’s AI algorithms analyze optical coherence tomography (OCT) images captured in routine clinical care to detect and monitor major retinal diseases – geographic atrophy, neovascular age-related macular degeneration, diabetic macular edema and retinal vein occlusion – which are the leading causes of vision loss globally. These tools enable earlier intervention and personalized treatment planning, especially for aging populations.
“With Topcon Healthcare’s infrastructure, we can scale reliable and affordable AI software globally,” said Prof. Hans Peter Schwarz, Chairman of the Board of RetInSight. “This partnership supports clinical care, drug discovery and therapeutic innovation worldwide.”
Other Articles to Explore
A Well-Used Platform
RetInSight’s platform, born from research at the Medical University of Vienna, Department of Ophthalmology and Optometry, under the direction of Prof. Dr. Ursula Schmidt-Erfurth, is already commercialized throughout Europe and is vendor-inclusive supporting interoperability across multiple OCT systems.
“RetInSight’s OCT-based AI expertise will help our global network of partners rapidly deploy innovations,” said Ali Tafreshi, CEO & President of Topcon Healthcare, Inc. “Integrated with our Harmony vendor-inclusive digital information system, we’re delivering clinical decision support and a scalable ecosystem for AI deployment.”
Already used in pharmaceutical trials, RetInSight’s algorithms also support AI-powered drug development and regulatory pathways, including advancing FDA clearances for U.S. indications.
“Together, we’re enabling seamless patient monitoring across the eye care continuum,” said Dr. Amir Sadeghipour, Managing Director of RetInSight. “This collaboration brings intelligent care to patients anywhere.”
Topcon notes in a press release “This acquisition marks a pivotal step toward global AI adoption in eye care, fostering a connected, developer-friendly ecosystem that drives better outcomes worldwide.”
Read about other recent news in Review of Optometric Business
Read about artificial intelligence innovation in ROB sister publication AI in Eye Care
